Document is current

Article History

Received: 14 January 2025

Accepted: 12 February 2025

First Online: 4 March 2025

Declarations

:

: Human tissues were analyzed under Brigham and Women’s Hospital/Dana-Farber Cancer Institute Institutional Review Board approval.

: Informed consent was obtained from all individual participants included in the study.

: Not required.

: M.M. and E.A.C. are inventors on a patent application covering the use of INCR1 as a therapeutic and diagnostic target. E.A.C. is an advisor to Bionaut Labs, Genenta, inc., Insightec, Inc., Seneca Therapeutics, Theravir. He has equity options in Bionaut Laboratories, Seneca Therapeutics, Ternalys Therapeutics. He is co-founder and on Board of Directors of Ternalys Therapeutics. Patents related to oncolytic viruses are under the possession of Brigham and Women’s Hospital (BWH) with E.A.C. as co-inventors. These patents have been licensed to Candel Therapeutics, Inc. Present and future milestone license fees and future royalty fees are distributed to BWH from Candel. G.J.F. has patents/pending royalties on the PD-L1/PD-1 pathway from Roche, Merck MSD, AstraZeneca, Bristol-Myers-Squibb, Merck KGA, Boehringer-Ingelheim, Dako, Leica, Mayo Clinic, Eli Lilly, and Novartis. G.J.F. has served on advisory boards for iTeos, NextPoint, IgM, GV20, IOME, Bioentre, Santa Ana Bio, Simcere of America, and Geode. G.J.F. has equity in Nextpoint, iTeos, IgM, Invaria, GV20, Bioentre, and Geode.